Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;19(3):327-337.
doi: 10.1007/s11914-021-00676-w. Epub 2021 May 14.

Genetic Determinants of Paget's Disease of Bone

Affiliations
Review

Genetic Determinants of Paget's Disease of Bone

Navnit S Makaram et al. Curr Osteoporos Rep. 2021 Jun.

Abstract

Purpose of review: To provide an overview of the role of genes and loci that predispose to Paget's disease of bone and related disorders.

Recent findings: Studies over the past ten years have seen major advances in knowledge on the role of genetic factors in Paget's disease of bone (PDB). Genome wide association studies have identified six loci that predispose to the disease whereas family based studies have identified a further eight genes that cause PDB. This brings the total number of genes and loci implicated in PDB to fourteen. Emerging evidence has shown that a number of these genes also predispose to multisystem proteinopathy syndromes where PDB is accompanied by neurodegeneration and myopathy due to the accumulation of abnormal protein aggregates, emphasising the importance of defects in autophagy in the pathogenesis of PDB. Genetic factors play a key role in the pathogenesis of PDB and the studies in this area have identified several genes previously not suspected to play a role in bone metabolism. Genetic testing coupled to targeted therapeutic intervention is being explored as a way of halting disease progression and improving outcome before irreversible skeletal damage has occurred.

Keywords: Paget's disease of bone; SQSTM1; genetics; multisystem proteinopathy; osteoclast.

PubMed Disclaimer

Conflict of interest statement

Professor Ralston reports grants from the European Commission during the conduct of the study and grants from Amgen, Eli Lilly, Novartis, and Pfizer, outside the submitted work; Mr Makaram declares no conflict of interest.

Figures

Fig. 1
Fig. 1
Genes implicated in Paget’s disease and related syndromes. Panel a shows some genes implicated in the pathogenesis of PDB which have effects on osteoclast differentiation and bone resorption. The gene products implicated in PDB are highlighted in red text. Panel b shows genes thought to affect intracellular signalling in osteoclasts and osteoclast precursors. The implicated gene products are highlighted in red and mostly affect the NFκB signalling pathway by interacting with SQSTM1 or genes that regulate signalling downstream of the RANK receptor. The ZNF678 gene encodes a transcription factor, but the exact mechanisms by which it predisposes to PDB are unclear. Abbreviations: c-fms - Colony Stimulating Factor 1 Receptor; M-CSF - Macrophage Colony Stimulating factor; RANK - Receptor Activator of Nuclear Factor Kappa B; RANKL - RANK Ligand; DC-STAMP - Dendritic Cell Specific Transmembrane Protein; OPG - Osteoprotegerin; RIN3 - Ras and Rab Interactor 3; IFN - Interferon; IFNR - Interferon Receptor; STAT - Signal Transducers and Activators of Transcription; TRAF 6 - Tumour Necrosis Factor Receptor Associated Factor 6; CYLD - Cylindromatosis; p62 - Sequestosome 1; aPKC - atypical Protein Kinase C; IKK - Inhibitor of Kappa B Kinase; IkB - Inhibitor of Kappa B; NFκB - Nuclear Factor Kappa B; OPTN - Optineurin, PFN1 - Profilin 1; NUP205 - Nucleoporin 205; ZNF687 - Zinc Finger Protein 687; Short Transmembrane Mitochondrial Protein 1.

References

    1. Makaram N, Woods L, Beattie N, Roberts SB, MacPherson GJ. Long-term outcomes following total hip and total knee arthroplasty in patients with Paget’s disease of bone (PDB) - a national study. Surgeon. 2020;S149-666X:30150–301507. - PubMed
    1. van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res. 2002;17:465–471. doi: 10.1359/jbmr.2002.17.3.465. - DOI - PubMed
    1. Gianfrancesco F, Rendina D, Merlotti D, Esposito T, Amyere M, Formicola D, Muscariello R, De Filippo G, Strazzullo P, Nuti R, Vikkula M, Gennari L. Giant cell tumor occurring in familial Paget’s disease of bone: report of clinical characteristics and linkage analysis of a large pedigree. J Bone Miner Res. 2013;28:341–350. doi: 10.1002/jbmr.1750. - DOI - PubMed
    1. Barker DJ. The epidemiology of Paget’s disease of bone. Br Med Bull. 1984;40:396–400. doi: 10.1093/oxfordjournals.bmb.a072011. - DOI - PubMed
    1. Detheridge FM, Guyer PB, Barker DJ. European distribution of Paget’s disease of bone. Br Med J (Clin Res Ed) 1982;285:1005–1008. doi: 10.1136/bmj.285.6347.1005. - DOI - PMC - PubMed

Publication types